{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T10:12:12Z","timestamp":1776334332691,"version":"3.51.2"},"reference-count":112,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1053\/j.seminoncol.2013.07.005","type":"journal-article","created":{"date-parts":[[2013,10,14]],"date-time":"2013-10-14T22:45:13Z","timestamp":1381790713000},"page":"618-633","source":"Crossref","is-referenced-by-count":21,"title":["Novel Generation of Agents With Proven Clinical Activity in Multiple Myeloma"],"prefix":"10.1053","volume":"40","author":[{"given":"Mar\u00eda-Victoria","family":"Mateos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrique M.","family":"Ocio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jes\u00fas F.","family":"San Miguel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1053\/j.seminoncol.2013.07.005_bib1","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"issue":"6152","key":"10.1053\/j.seminoncol.2013.07.005_bib2","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/331192a0","article-title":"Identity of the 19S 'prosome' particle with the large multifunctional protease complex of mammalian cells (the proteasome)","volume":"331","author":"Arrigo","year":"1988","journal-title":"Nature"},{"issue":"11","key":"10.1053\/j.seminoncol.2013.07.005_bib3","first-page":"2615","article-title":"Proteasome inhibitors: a novel class of potent and effective antitumor agents","volume":"59","author":"Adams","year":"1999","journal-title":"Cancer Res"},{"issue":"7","key":"10.1053\/j.seminoncol.2013.07.005_bib4","first-page":"3071","article-title":"The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells","volume":"61","author":"Hideshima","year":"2001","journal-title":"Cancer Res"},{"issue":"17","key":"10.1053\/j.seminoncol.2013.07.005_bib5","first-page":"4996","article-title":"Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model","volume":"62","author":"LeBlanc","year":"2002","journal-title":"Cancer Res"},{"issue":"26","key":"10.1053\/j.seminoncol.2013.07.005_bib6","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1053\/j.seminoncol.2013.07.005_bib7","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1053\/j.seminoncol.2013.07.005_bib8","doi-asserted-by":"crossref","first-page":"3557","DOI":"10.1182\/blood-2006-08-036947","article-title":"Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial","volume":"110","author":"Richardson","year":"2007","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.seminoncol.2013.07.005_bib9","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2174\/1389203043379774","article-title":"Proteasome function in antigen presentation: immunoproteasome complexes, peptide production, and interactions with viral proteins","volume":"5","author":"Rivett","year":"2004","journal-title":"Curr Protein Pept Sci"},{"issue":"6","key":"10.1053\/j.seminoncol.2013.07.005_bib10","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1073\/pnas.95.6.2727","article-title":"The ubiquitin-proteasome pathway: the complexity and myriad functions of proteins death","volume":"95","author":"Ciechanover","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"22","key":"10.1053\/j.seminoncol.2013.07.005_bib11","doi-asserted-by":"crossref","first-page":"14374","DOI":"10.1073\/pnas.202445099","article-title":"Molecular sequelae of proteasome inhibition in human multiple myeloma cells","volume":"99","author":"Mitsiades","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1053\/j.seminoncol.2013.07.005_bib12","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1182\/blood-2002-08-2543","article-title":"Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341","volume":"101","author":"Hideshima","year":"2003","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.seminoncol.2013.07.005_bib13","first-page":"191","article-title":"Targeting proteasome inhibition in hematologic malignancies","volume":"7","author":"Hideshima","year":"2003","journal-title":"Rev Clin Exp Hematol"},{"issue":"2","key":"10.1053\/j.seminoncol.2013.07.005_bib14","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.cell.2006.05.043","article-title":"Distinct ubiquitin-ligase complexes define convergent pathways for the degradation of ER proteins","volume":"126","author":"Carvalho","year":"2006","journal-title":"Cell"},{"issue":"6","key":"10.1053\/j.seminoncol.2013.07.005_bib15","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.semcdb.2007.09.008","article-title":"Ubiquitin receptors and ERAD: a network of pathways to the proteasome","volume":"18","author":"Raasi","year":"2007","journal-title":"Semin Cell Dev Biol"},{"issue":"49","key":"10.1053\/j.seminoncol.2013.07.005_bib16","doi-asserted-by":"crossref","first-page":"6867","DOI":"10.1038\/sj.onc.1203219","article-title":"How NF-kappaB is activated: the role of the IkappaB kinase (IKK) complex","volume":"18","author":"Karin","year":"1999","journal-title":"Oncogene"},{"issue":"1","key":"10.1053\/j.seminoncol.2013.07.005_bib17","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1634\/theoncologist.7-1-9","article-title":"Development of the proteasome inhibitor PS-341","volume":"7","author":"Adams","year":"2002","journal-title":"Oncologist"},{"issue":"17","key":"10.1053\/j.seminoncol.2013.07.005_bib18","doi-asserted-by":"crossref","first-page":"7896","DOI":"10.1158\/0008-5472.CAN-05-0506","article-title":"Effects of PS-341 on the activity and composition of proteasomes in multiple myeloma cells","volume":"65","author":"Altun","year":"2005","journal-title":"Cancer Res"},{"issue":"5","key":"10.1053\/j.seminoncol.2013.07.005_bib19","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","article-title":"Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study","volume":"12","author":"Moreau","year":"2011","journal-title":"Lancet Oncol"},{"issue":"22","key":"10.1053\/j.seminoncol.2013.07.005_bib20","doi-asserted-by":"crossref","first-page":"4420","DOI":"10.1200\/JCO.2002.01.133","article-title":"Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies","volume":"20","author":"Orlowski","year":"2002","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1053\/j.seminoncol.2013.07.005_bib21","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1365-2141.2004.05188.x","article-title":"A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma","volume":"127","author":"Jagannath","year":"2004","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1053\/j.seminoncol.2013.07.005_bib22","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1200\/JCO.2005.11.030","article-title":"Proteasome inhibition as a novel therapeutic target in human cancer","volume":"23","author":"Rajkumar","year":"2005","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1053\/j.seminoncol.2013.07.005_bib23","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.1200\/JCO.2006.10.5460","article-title":"Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression","volume":"25","author":"Orlowski","year":"2007","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1053\/j.seminoncol.2013.07.005_bib24","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1182\/blood-2002-06-1768","article-title":"The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications","volume":"101","author":"Mitsiades","year":"2003","journal-title":"Blood"},{"issue":"5","key":"10.1053\/j.seminoncol.2013.07.005_bib25","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1182\/blood-2010-02-268862","article-title":"Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma","volume":"116","author":"Richardson","year":"2010","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.seminoncol.2013.07.005_bib26","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1182\/blood-2011-02-334755","article-title":"Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1\/2 Multiple Myeloma Research Consortium trial","volume":"118","author":"Jakubowiak","year":"2011","journal-title":"Blood"},{"issue":"34","key":"10.1053\/j.seminoncol.2013.07.005_bib27","doi-asserted-by":"crossref","first-page":"5713","DOI":"10.1200\/JCO.2009.22.2679","article-title":"Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed\/refractory multiple myeloma","volume":"27","author":"Richardson","year":"2009","journal-title":"J Clin Oncol"},{"issue":"30","key":"10.1053\/j.seminoncol.2013.07.005_bib28","doi-asserted-by":"crossref","first-page":"4621","DOI":"10.1200\/JCO.2009.27.9158","article-title":"Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial","volume":"28","author":"Harousseau","year":"2010","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1053\/j.seminoncol.2013.07.005_bib29","first-page":"40","article-title":"HOVON-65\/GMMG-HD4 Randomized phase III trial comparing bortezomib, doxorubicin, dexamethasone (PAD) vs VAD followed by high-dose melphalan (HDM) and maintenance with bortezomib or thalidomide in patients with newly diagnosed multiple myeloma (MM)","volume":"116","author":"Sonneveld","year":"2010","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"9758","key":"10.1053\/j.seminoncol.2013.07.005_bib30","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/S0140-6736(10)61424-9","volume":"376","author":"Cavo","year":"2010","journal-title":"Lancet"},{"issue":"21","key":"10.1053\/j.seminoncol.2013.07.005_bib31","first-page":"307","article-title":"A phase III PETHEMA\/GEM study of induction therapy prior autologous stem cell transplantation (ASCT) in multiple myeloma: superiority of VTD (bortezomib\/thalidomide\/dexamethasone) over TD and VBMCP\/VBAD plus bortezomib","volume":"116","author":"Rosinol","year":"2010","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"9","key":"10.1053\/j.seminoncol.2013.07.005_bib32","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma","volume":"359","author":"San Miguel","year":"2008","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1053\/j.seminoncol.2013.07.005_bib33","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/S1470-2045(10)70187-X","volume":"11","author":"Mateos","year":"2010","journal-title":"Lancet Oncol"},{"issue":"34","key":"10.1053\/j.seminoncol.2013.07.005_bib34","doi-asserted-by":"crossref","first-page":"5101","DOI":"10.1200\/JCO.2010.29.8216","article-title":"Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial","volume":"28","author":"Palumbo","year":"2010","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1053\/j.seminoncol.2013.07.005_bib35","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1182\/blood-2007-01-065888","article-title":"Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma","volume":"110","author":"Kuhn","year":"2007","journal-title":"Blood"},{"issue":"13","key":"10.1053\/j.seminoncol.2013.07.005_bib36","doi-asserted-by":"crossref","first-page":"6383","DOI":"10.1158\/0008-5472.CAN-06-4086","article-title":"Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome","volume":"67","author":"Demo","year":"2007","journal-title":"Cancer Res"},{"issue":"22","key":"10.1053\/j.seminoncol.2013.07.005_bib37","doi-asserted-by":"crossref","first-page":"7085","DOI":"10.1158\/1078-0432.CCR-09-0822","article-title":"A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies","volume":"15","author":"O\u2019Connor","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"17","key":"10.1053\/j.seminoncol.2013.07.005_bib38","doi-asserted-by":"crossref","first-page":"4830","DOI":"10.1158\/1078-0432.CCR-11-3007","article-title":"A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma","volume":"18","author":"Alsina","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1053\/j.seminoncol.2013.07.005_bib39","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.clml.2012.08.003","article-title":"An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma","volume":"12","author":"Jagannath","year":"2012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"14","key":"10.1053\/j.seminoncol.2013.07.005_bib40","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1182\/blood-2012-05-425934","article-title":"A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma","volume":"120","author":"Siegel","year":"2012","journal-title":"Blood"},{"issue":"24","key":"10.1053\/j.seminoncol.2013.07.005_bib41","doi-asserted-by":"crossref","first-page":"5661","DOI":"10.1182\/blood-2012-03-414359","article-title":"An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and\/or refractory multiple myeloma","volume":"119","author":"Vij","year":"2012","journal-title":"Blood"},{"issue":"21","key":"10.1053\/j.seminoncol.2013.07.005_bib42","first-page":"1877","article-title":"Multivariate modelling reveals evidence of a dose-response relationship in phase 2 studies of single-agent carfilzomib","volume":"118","author":"Squifflet","year":"2011","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"6","key":"10.1053\/j.seminoncol.2013.07.005_bib43","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/j.1365-2141.2012.09232.x","article-title":"An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and\/or refractory multiple myeloma who have been previously treated with bortezomib","volume":"158","author":"Vij","year":"2012","journal-title":"Br J Haematol"},{"issue":"21","key":"10.1053\/j.seminoncol.2013.07.005_bib44","first-page":"1875","article-title":"Unfavorable cytogenetic characteristics do not adversely impact response rates in patients with relapsed and\/or refractory multiple myeloma treated with single-agent carfilzomib on the 003 (A1) study","volume":"118","author":"Jakubowiak","year":"2011","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminoncol.2013.07.005_bib45","doi-asserted-by":"crossref","DOI":"10.1038\/leu.2013.29","article-title":"Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety","author":"Badros","year":"2013","journal-title":"Leukemia"},{"issue":"21","key":"10.1053\/j.seminoncol.2013.07.005_bib46","first-page":"1876","article-title":"Integrated safety from phase 2 studies of monotherapy carfilzomib in patients with relapsed and refractory multiple myeloma (MM): an updated analysis","volume":"118","author":"Singhal","year":"2011","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"15 suppl","key":"10.1053\/j.seminoncol.2013.07.005_bib47","first-page":"8025","article-title":"Interim results from PX-171-006, a phase (Ph) II multicenter dose-expansion study of carfilzomib (CFZ), lenalidomide (LEN), and low-dose dexamethasone (loDex) in relapsed and\/or refractory multiple myeloma (R\/R MM)","volume":"29","author":"Wang","year":"2011","journal-title":"ASCO Meeting Abstracts"},{"issue":"9","key":"10.1053\/j.seminoncol.2013.07.005_bib48","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1182\/blood-2012-04-422683","article-title":"A phase 1\/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma","volume":"120","author":"Jakubowiak","year":"2012","journal-title":"Blood"},{"issue":"21","key":"10.1053\/j.seminoncol.2013.07.005_bib49","first-page":"633","article-title":"Carfilzomib combined with thalidomide and dexamethasone (CARTHADEX) as induction treatment prior to high-dose melphalan (HDM) in newly diagnosed patients with multiple myeloma (MM). A trial of the European Myeloma Network EMN","volume":"118","author":"Sonneveld","year":"2011","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"15 suppl","key":"10.1053\/j.seminoncol.2013.07.005_bib50","first-page":"TPS225","article-title":"A randomized, multicenter, phase (Ph) III study comparing carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (Dex) to LEN and Dex in patients (Pts) with relapsed multiple myeloma (MM)","volume":"29","author":"Moreau","year":"2011","journal-title":"ASCO Meeting Abstracts"},{"issue":"9","key":"10.1053\/j.seminoncol.2013.07.005_bib51","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1021\/jm801329v","article-title":"Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047)","volume":"52","author":"Zhou","year":"2009","journal-title":"J Med Chem"},{"issue":"15 suppl","key":"10.1053\/j.seminoncol.2013.07.005_bib52","first-page":"3075","article-title":"A phase I, open-label, dose-escalation study of the novel oral proteasome inhibitor (PI) ONX 0912 in patients with advanced refractory or recurrent solid tumors","volume":"29","author":"Papadopoulos","year":"2011","journal-title":"ASCO Meeting Abstracts"},{"issue":"21","key":"10.1053\/j.seminoncol.2013.07.005_bib53","first-page":"203","article-title":"A phase 1b dose-escalation study of split-dose oprozomib (ONX0912) in patients with hematologic malignancies","volume":"120","author":"Savona","year":"2012","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"16","key":"10.1053\/j.seminoncol.2013.07.005_bib54","doi-asserted-by":"crossref","first-page":"5311","DOI":"10.1158\/1078-0432.CCR-11-0476","article-title":"In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells","volume":"17","author":"Chauhan","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"21","key":"10.1053\/j.seminoncol.2013.07.005_bib55","first-page":"1433","article-title":"Flat-dosing versus BSA-based dosing for MLN9708, an investigational proteasome inhibitor: population pharmacokinetic (PK) analysis of pooled data from 4 phase-1 studies","volume":"118","author":"Gupta","year":"2011","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"21","key":"10.1053\/j.seminoncol.2013.07.005_bib56","first-page":"816","article-title":"Weekly dosing of the investigational oral proteasome inhibitor MLN9708 in patients with relapsed and\/or refractory multiple myeloma: results from a phase 1 dose-escalation study","volume":"118","author":"Kumar","year":"2011","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"21","key":"10.1053\/j.seminoncol.2013.07.005_bib57","first-page":"301","article-title":"Investigational agent MLN9708, an oral proteasome inhibitor, in patients (Pts) with relapsed and\/or refractory multiple myeloma (MM): results from the expansion cohorts of a phase 1 dose-escalation study","volume":"118","author":"Richardson","year":"2011","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"21","key":"10.1053\/j.seminoncol.2013.07.005_bib58","first-page":"332","article-title":"A phase 1\/2 study of weekly MLN9708, an investigational oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma (MM)","volume":"120","author":"Kumar","year":"2012","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"21","key":"10.1053\/j.seminoncol.2013.07.005_bib59","first-page":"479","article-title":"Phase 1\/2 study of oral MLN9708, a novel, investigational proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma (MM)","volume":"118","author":"Berdeja","year":"2011","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"8","key":"10.1053\/j.seminoncol.2013.07.005_bib60","first-page":"961","article-title":"A novel proteasome inhibitor NPI-0052 as an anticancer therapy","volume":"95","author":"Chauhan","year":"2006","journal-title":"BrJCancer"},{"issue":"5","key":"10.1053\/j.seminoncol.2013.07.005_bib61","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ccr.2005.10.013","article-title":"A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib","volume":"8","author":"Chauhan","year":"2005","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1053\/j.seminoncol.2013.07.005_bib62","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1182\/blood-2007-08-105601","article-title":"Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma","volume":"111","author":"Chauhan","year":"2008","journal-title":"Blood"},{"issue":"21","key":"10.1053\/j.seminoncol.2013.07.005_bib63","first-page":"302","article-title":"Phase 1 clinical evaluation of twice-weekly marizomib (NPI-0052), a novel proteasome inhibitor, in patients with relapsed\/refractory multiple myeloma (MM)","volume":"118","author":"Richardson","year":"2011","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"5971","key":"10.1053\/j.seminoncol.2013.07.005_bib64","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1126\/science.1177319","article-title":"Identification of a primary target of thalidomide teratogenicity","volume":"327","author":"Ito","year":"2010","journal-title":"Science"},{"issue":"18","key":"10.1053\/j.seminoncol.2013.07.005_bib65","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.1182\/blood-2011-05-356063","article-title":"Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide","volume":"118","author":"Zhu","year":"2011","journal-title":"Blood"},{"issue":"19","key":"10.1053\/j.seminoncol.2013.07.005_bib66","doi-asserted-by":"crossref","first-page":"5157","DOI":"10.1182\/blood-2010-10-314278","article-title":"IMiD immunomodulatory compounds block C\/EBP{beta} translation through eIF4E down-regulation resulting in inhibition of MM","volume":"117","author":"Li","year":"2011","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.seminoncol.2013.07.005_bib67","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1365-2141.2011.08689.x","article-title":"Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response","volume":"154","author":"Lopez-Girona","year":"2011","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1053\/j.seminoncol.2013.07.005_bib68","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1182\/blood.V96.9.2943","article-title":"Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy","volume":"96","author":"Hideshima","year":"2000","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.seminoncol.2013.07.005_bib69","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2174\/156800910791054239","article-title":"Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function","volume":"10","author":"Gandhi","year":"2010","journal-title":"Curr Cancer Drug Targets"},{"issue":"18","key":"10.1053\/j.seminoncol.2013.07.005_bib70","doi-asserted-by":"crossref","first-page":"7347","DOI":"10.1158\/0008-5472.CAN-08-4898","article-title":"Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism","volume":"69","author":"Escoubet-Lozach","year":"2009","journal-title":"Cancer Res"},{"issue":"12","key":"10.1053\/j.seminoncol.2013.07.005_bib71","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1038\/sj.leu.2402295","article-title":"Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications","volume":"15","author":"Gupta","year":"2001","journal-title":"Leukemia"},{"issue":"2","key":"10.1053\/j.seminoncol.2013.07.005_bib72","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1182\/blood-2005-10-4184","article-title":"Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications","volume":"108","author":"Chang","year":"2006","journal-title":"Blood"},{"issue":"14","key":"10.1053\/j.seminoncol.2013.07.005_bib73","doi-asserted-by":"crossref","first-page":"4650","DOI":"10.1158\/1078-0432.CCR-07-4405","article-title":"lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells","volume":"14","author":"Wu","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1053\/j.seminoncol.2013.07.005_bib74","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s00262-008-0620-4","article-title":"The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells","volume":"58","author":"Galustian","year":"2009","journal-title":"Cancer Immunol Immunother"},{"issue":"7","key":"10.1053\/j.seminoncol.2013.07.005_bib75","first-page":"2427","article-title":"Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug","volume":"118","author":"Ramsay","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1053\/j.seminoncol.2013.07.005_bib76","doi-asserted-by":"crossref","unstructured":"Davies F, Baz R. Lenalidomide mode of action: linking bench and clinical findings. Blood Rev. 2010;24 Suppl 1:S13-9","DOI":"10.1016\/S0268-960X(10)70004-7"},{"issue":"2","key":"10.1053\/j.seminoncol.2013.07.005_bib77","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/blood.V98.2.492","article-title":"Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients","volume":"98","author":"Barlogie","year":"2001","journal-title":"Blood"},{"issue":"5","key":"10.1053\/j.seminoncol.2013.07.005_bib78","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1111\/j.1365-2141.2005.05914.x","article-title":"A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma","volume":"132","author":"Glasmacher","year":"2006","journal-title":"BrJHaematol"},{"issue":"11","key":"10.1053\/j.seminoncol.2013.07.005_bib79","first-page":"3563","article-title":"A randomized comparison of dexamethasone + thalidomide (Dex\/Thal) vs Dex + placebo (Dex\/P) in patients (pts) with relapsing multiple myeloma (MM)","volume":"108","author":"Fermand","year":"2006","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"4","key":"10.1053\/j.seminoncol.2013.07.005_bib80","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1038\/sj.leu.2403322","article-title":"The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed\/refractory multiple myeloma","volume":"18","author":"Garcia-Sanz","year":"2004","journal-title":"Leukemia"},{"issue":"22","key":"10.1053\/j.seminoncol.2013.07.005_bib81","doi-asserted-by":"crossref","first-page":"5752","DOI":"10.1182\/blood-2011-05-355081","article-title":"Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma","volume":"118","author":"Moreau","year":"2011","journal-title":"Blood"},{"issue":"8","key":"10.1053\/j.seminoncol.2013.07.005_bib82","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1182\/blood-2012-02-408922","article-title":"Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA\/GEM study","volume":"120","author":"Rosinol","year":"2012","journal-title":"Blood"},{"issue":"5","key":"10.1053\/j.seminoncol.2013.07.005_bib83","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1182\/blood-2011-03-341669","article-title":"Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials","volume":"118","author":"Fayers","year":"2011","journal-title":"Blood"},{"issue":"5","key":"10.1053\/j.seminoncol.2013.07.005_bib84","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1182\/blood-2011-02-338665","article-title":"Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation","volume":"118","author":"Morgan","year":"2011","journal-title":"Blood"},{"issue":"9","key":"10.1053\/j.seminoncol.2013.07.005_bib85","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1182\/blood-2002-03-0996","article-title":"Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma","volume":"100","author":"Richardson","year":"2002","journal-title":"Blood"},{"issue":"10","key":"10.1053\/j.seminoncol.2013.07.005_bib86","doi-asserted-by":"crossref","first-page":"3458","DOI":"10.1182\/blood-2006-04-015909","article-title":"A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma","volume":"108","author":"Richardson","year":"2006","journal-title":"Blood"},{"issue":"21","key":"10.1053\/j.seminoncol.2013.07.005_bib87","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa070596","article-title":"Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America","volume":"357","author":"Weber","year":"2007","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1053\/j.seminoncol.2013.07.005_bib88","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1053\/j.seminoncol.2013.07.005_bib89","doi-asserted-by":"crossref","first-page":"4137","DOI":"10.1182\/blood-2008-10-184135","article-title":"Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom)","volume":"113","author":"Knop","year":"2009","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.seminoncol.2013.07.005_bib90","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1365-2141.2007.06538.x","article-title":"Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients","volume":"137","author":"Morgan","year":"2007","journal-title":"Br J Haematol"},{"issue":"16","key":"10.1053\/j.seminoncol.2013.07.005_bib91","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1200\/JCO.2004.10.052","article-title":"Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma","volume":"22","author":"Schey","year":"2004","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1053\/j.seminoncol.2013.07.005_bib92","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1365-2141.2008.07013.x","article-title":"Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation","volume":"141","author":"Streetly","year":"2008","journal-title":"Br J Haematol"},{"issue":"21","key":"10.1053\/j.seminoncol.2013.07.005_bib93","first-page":"864","volume":"116","author":"Richardson","year":"2010","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"21","key":"10.1053\/j.seminoncol.2013.07.005_bib94","first-page":"634","volume":"118","author":"Richardson","year":"2011","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"30","key":"10.1053\/j.seminoncol.2013.07.005_bib95","doi-asserted-by":"crossref","first-page":"5008","DOI":"10.1200\/JCO.2009.23.6802","article-title":"Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma","volume":"27","author":"Lacy","year":"2009","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1053\/j.seminoncol.2013.07.005_bib96","first-page":"2942","article-title":"Long term outcomes of pomalidomide and dexamethasone in patients with relapsed multiple myeloma: analysis 4 years after the original cohort","volume":"118","author":"Mikhael","year":"2011","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"11","key":"10.1053\/j.seminoncol.2013.07.005_bib97","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1038\/leu.2009.147","article-title":"Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma","volume":"23","author":"Dimopoulos","year":"2009","journal-title":"Leukemia"},{"issue":"21","key":"10.1053\/j.seminoncol.2013.07.005_bib98","first-page":"1964","article-title":"Efficacy of retreatment with immunomodulatory compounds in patients receiving initial therapy for newly diagnosed multiple myeloma","volume":"116","author":"Madan","year":"2010","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"7","key":"10.1053\/j.seminoncol.2013.07.005_bib99","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1182\/blood-2011-04-350009","article-title":"Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma","volume":"118","author":"Madan","year":"2011","journal-title":"Blood"},{"issue":"21","key":"10.1053\/j.seminoncol.2013.07.005_bib100","first-page":"134","article-title":"Reversibility of the resistance to lenalidomide and pomalidomide and absence of cross-resistance in a murine model of MM","volume":"118","author":"Ocio","year":"2011","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"11","key":"10.1053\/j.seminoncol.2013.07.005_bib101","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1038\/leu.2010.190","article-title":"Pomalidomide (CC4047) plus low dose dexamethasone (Pom\/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)","volume":"24","author":"Lacy","year":"2010","journal-title":"Leukemia"},{"issue":"21","key":"10.1053\/j.seminoncol.2013.07.005_bib102","first-page":"3963","article-title":"Pomalidomide and dexamethasone in relapsed myeloma: results of 225 patients treated in five cohorts over three years","volume":"118","author":"Lacy","year":"2011","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"11","key":"10.1053\/j.seminoncol.2013.07.005_bib103","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1182\/blood-2011-04-348896","article-title":"Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of two dosing strategies in dual-refractory disease","volume":"118","author":"Lacy","year":"2011","journal-title":"Blood"},{"issue":"21","key":"10.1053\/j.seminoncol.2013.07.005_bib104","first-page":"812","article-title":"High response rates to pomalidomide and dexamethasone in patients with refractory myeloma, final analysis of IFM 2009-02","volume":"118","author":"Leleu","year":"2011","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"21","key":"10.1053\/j.seminoncol.2013.07.005_bib105","first-page":"859","article-title":"Phase 2 study of 2 modalities of pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. IFM 2009-02","volume":"116","author":"Leleu","year":"2010","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"21","key":"10.1053\/j.seminoncol.2013.07.005_bib106","article-title":"Pomalidomide in combination with low-dose dexamethasone: demonstrates a significant progression free survival and overall survival advantage, in relapsed\/refractory MM: a phase 3, multicenter, randomized, open-label study","volume":"120","author":"Dimopoulos","year":"2012","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"21","key":"10.1053\/j.seminoncol.2013.07.005_bib107","first-page":"446","article-title":"Pomalidomide cyclophosphamide and prednisone (PCP) treatment for relapsed\/refractory multiple myeloma","volume":"120","author":"Palumbo","year":"2012","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"21","key":"10.1053\/j.seminoncol.2013.07.005_bib108","first-page":"77","article-title":"ClaPD (clarithromycin, pomalidomide, dexamethasone) therapy in relapsed or refractory multiple myeloma","volume":"120","author":"Mark","year":"2012","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"21","key":"10.1053\/j.seminoncol.2013.07.005_bib109","first-page":"74","article-title":"A multi-center phase I\/II trial of carfilzomib and pomalidomide with dexamethasone (Car-Pom-d) in patients with relapsed\/refractory multiple myeloma","volume":"120","author":"Shah","year":"2012","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"21","key":"10.1053\/j.seminoncol.2013.07.005_bib110","first-page":"985","article-title":"Results of PX-171-003-A1, an open-label, single-arm, phase 2 (Ph 2) study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (MM)","volume":"116","author":"diCapua Siegel","year":"2010","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"15 suppl","key":"10.1053\/j.seminoncol.2013.07.005_bib111","first-page":"8034","article-title":"Weekly dosing of the investigational oral proteasome inhibitor MLN9708 in patients (pts) with relapsed\/refractory multiple myeloma (MM): a phase I study","volume":"30","author":"Kumar","year":"2012","journal-title":"ASCO Meeting Abstracts"},{"issue":"15 suppl","key":"10.1053\/j.seminoncol.2013.07.005_bib112","first-page":"8017","article-title":"Phase I study of twice-weekly dosing of the investigational oral proteasome inhibitor MLN9708 in patients (pts) with relapsed and\/or refractory multiple myeloma (MM)","volume":"30","author":"Lonial","year":"2012","journal-title":"ASCO Meeting Abstracts"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775413001292?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775413001292?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,5]],"date-time":"2020-08-05T23:55:31Z","timestamp":1596671731000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775413001292"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":112,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["S0093775413001292"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2013.07.005","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]}}}